Status:
UNKNOWN
Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Spontaneous Bacterial Peritonitis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
SBP is a common complication of cirrhotics with associated increased mortality. After first episode of SBP there is increased risk of again developing SBP, with increased chance of developing resistan...
Detailed Description
Hypothesis:-Rifaximin will be more effective in decreasing the incidence of SBP in patients with cirrhosis and prior episode of SBP AIM:-.To study the efficacy and safety of Rifaximin vs Norfloxacin ...
Eligibility Criteria
Inclusion
- Age\>18 years
- Cirrhosis (of any etiology) with ascites
- Prior incident SBP
Exclusion
- Allergy to norfloxacin or rifaximin
- Recent history of upper gastrointestinal bleed (UGIB) within 2 weeks
- Patients with a history of multiple episodes of SBP
- Patients with inoperable or not treatable HCC or other non-hepatic malignancy
- Patients on immunosuppression
- HIV infected
- Post liver transplant
- Recent (\<6 months) abdominal surgery
- Pregnant/lactating women
- Other causes of ascites like tubercular or malignancy
- Patients developing SBP on Norfloxcacin
Key Trial Info
Start Date :
January 5 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT06199843
Start Date
January 5 2024
End Date
December 31 2024
Last Update
January 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr Jaya Benjamin
New Delhi, National Capital Territory of Delhi, India, 110070